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Statement of findings
Serum and synovial tissue expression of the matrix metalloproteinase (MMP)-2 and -9 and
their molecular regulators, MMP-14 and TIMP-2 was examined in 28 patients with
inflammatory early synovitis and 4 healthy volunteers and correlated with the presence of
erosions in the patients. Immunohistological staining of MMP-2, MMP-14 and TIMP-2
localized to corresponding areas in the synovial lining layer and was almost absent in normal
synovium. Patients with radiographic erosions had significantly higher levels of active MMP-2
than patients with no erosions, suggesting that activated MMP-2 levels in synovial tissue
may be a marker for a more aggressive synovial lesion.
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toid arthritis; TIMP = tissue inhibitor of metalloproteinase.
Introduction: In cancer the gelatinases [matrix metalloproteinase
(MMP)-2 and MMP-9] have been shown to be associated with
tissue invasion and metastatic disease. In patients with
inflammatory arthritis the gelatinases are expressed in the
synovial membrane, and have been implicated in synovial tissue
invasion into adjacent cartilage and bone. It is hypothesized
that an imbalance between the activators and inhibitors of the
gelatinases results in higher levels of activity, enhanced local
proteolysis, and bone erosion.
Objectives: To determine whether the expression and activity
levels of MMP-2 and MMP-9, and their regulators MMP-14 and
tissue inhibitor of metalloproteinase (TIMP), are associated with
early erosion formation in patients with synovitis of recent onset.
Patients and method: A subset of 66 patients was selected
from a larger early synovitis cohort on the basis of tissue
availability for the study of synovial tissue and serum
gelatinase expression. Patients with peripheral joint synovitis
of less than 1 years’ duration were evaluated clinically and
serologically on four visits over a period of 12 months. At the
initial visit, patients underwent a synovial tissue biopsy of one
swollen joint, and patients had radiographic evaluation of
hands and feet initially and at 1 year. Serum MMP-1, MMP-2,
MMP-9, MMP-14, and TIMP-1 and TIMP-2 levels were
determined, and synovial tissue was examined by immuno-
histology for the expression of MMP-2 and MMP-9, and their
molecular regulators. Gelatinolytic activity for MMP-2 and
MMP-9 was quantified using a sensitive, tissue-based gel
zymography technique. Four healthy individuals underwent
closed synovial biopsy and their synovial tissues were similarly
analyzed.
http://arthritis-research.com/content/2/2/145Arthritis Research    Vol 2 No 2 Goldbach-Mansky et al
Results: Of the 66 patients studied, 45 fulfilled American
College of Rheumatology criteria for rheumatoid arthritis (RA),
with 32 (71%) being rheumatoid factor positive. Of the 21 non-
RA patients, seven had a spondylarthropathy and 14 had
undifferentiated arthritis. Radiographically, 12 of the RA patients
had erosions at multiple sites by 1 year, whereas none of the
non-RA patients had developed erosive disease of this extent.
In the tissue, latent MMP-2 was widely expressed in the
synovial lining layer and in areas of stromal proliferation in the
sublining layer and stroma, whereas MMP-9 was expressed
more sparsely and focally. MMP-14, TIMP-2, and MMP-2 were
all detected in similar areas of the lining layer on consecutive
histologic sections. Tissue expression of MMP-14, the
activator for pro-MMP-2, was significantly higher in RA than in
non-RA patients (8.4±5 versus 3.7±4 cells/high-power field;
P=0.009). In contrast, the expression of TIMP-2, an inhibitor
of MMP-2, was lower in the RA than in the non-RA samples
(25±12 versus 39±9 cells/high-power field; P=0.01).
Synovial tissue expressions of MMP-2, MMP-14, and TIMP-2
were virtually undetectable in normal synovial tissue samples.
The synovial tissue samples of patients with erosive disease
had significantly higher levels of active MMP-2 than did those
of patients without erosions (Fig. 1). Tissue expression of
MMP-2 and MMP-9, however, did not correlate with the serum
levels of these enzymes.
With the exception of serum MMP-2, which was not elevated
over normal, serum levels of all of the other MMPs and TIMPs
were elevated to varying degrees, and were not predictive of
erosive disease. Interestingly, MMP-1 and C-reactive protein,
both of which were associated with the presence of erosions,
were positively correlated with each other (r=0.42; P<0.001).
Discussion: MMP-2 and MMP-9 are thought to play an
important role in the evolution of joint erosions in patients with
an inflammatory arthritis. Most studies have concentrated on the
contribution of MMP-9 to the synovitis, because synovial fluid
and serum MMP-9 levels are markedly increased in inflammatory
arthropathies. Previously reported serum levels of MMP-9 have
varied widely. In the present sample of patients with synovitis of
recent onset, serum MMP-9 levels were elevated in only 21%.
Moreover, these elevations were not specific for RA, the tissue
expression of MMP-9 was focal, and the levels of MMP-9
activity were not well correlated with early erosions. Although
serum MMP-2 levels were not of prognostic value, high synovial
tissue levels of MMP-2 activity were significantly correlated with
the presence of early erosions. This may reflect augmented
activation of MMP-2 by the relatively high levels of MMP-14 and
low levels of TIMP-2 seen in these tissues. We were able to
localize the components of this trimolecular complex to the
synovial lining layer in consecutive tissue sections, a finding that
is consistent with their colocalization.
In conclusion, we have provided evidence that active MMP-2
complexes are detectable in the inflamed RA synovium and
may be involved in the development of early bony erosions.
These results suggest that strategies to inhibit the activation of
MMP-2 may have the potential for retarding or preventing early
erosions in patients with inflammatory arthritis.
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Introduction
Radiographic erosions are characteristic of a number of
chronic inflammatory arthropathies, and are associated
with articular destruction leading to functional loss and
disability [1,2]. The prevention or retardation of erosions is
a major objective for early therapeutic interventions in
patients with new onset arthritis [3]. Although the patho-
logic processes that underlie the development of erosions
are incompletely understood, a considerable body of evi-
dence has suggested that a pannus of cells that originate
in chronically inflamed, proliferative synovial tissue
becomes locally invasive, and enzymatically degrades the
matrix of the articular cartilage and periarticular bone [4].
Although a number of enzymes have been shown to be
involved in erosion formation, several members of the
Figure 1
Matrix metalloproteinase (MMP)-2 and MMP-9 gelatinolytic activity in
patients with erosions, in patients with no erosions, and in normal
control individuals.
Gelatinolytic activity Erosions No erosions Normals
Active MMP-2 activity (ng/mg) 3.5 ± 2.1 1.9 ± 2.5 1.3 ± 0.5
Total MMP-2 activity (ng/mg) 18.9 ± 9.4 10.9 ± 8.1 5.7 ± 0.7
MMP-9 activity (ng/mg) 42.6 ± 54.1 25.5 ± 75.2 4.0 ± 0.7http://arthritis-research.com/content/2/2/145
matrix metalloproteinase (MMP) family are thought to play
a central role in the degradation of the extracellular matrix
of articular bone and cartilage. Of the MMPs, the collage-
nases [5,6] and stromelysins [7] have been the best
studied, and marked elevations in serum and synovial
levels have been found in rheumatoid arthritis (RA) [8]. A
number of studies have shown that the serum and synovial
levels of both gelatinases MMP-2 [9,10] and MMP-9
[11–13] are similarly elevated in RA. Although both of
these MMPs are expressed at the junction between syn-
ovial pannus and cartilage or bone [14], further evidence
of their direct role in erosion formation is lacking. In addi-
tion members of this subfamily of MMPs are involved in
the invasiveness of cancers [15,16], and thus may also
play a similar role in the invasion of synovial pannus.
The regulation of MMP activity is complex, and occurs at
multiple levels [17–19]. In most cases, MMPs are
secreted as proenzymes and then undergo extracellular
activation. Few studies have evaluated the levels of active
MMPs in situ. Gel zymography has proved to be a sensi-
tive and effective method of detecting the activity of gelati-
nases in small tissue samples [20]. In the present study
we evaluated the levels of active MMP-2 and MMP-9 in
small synovial biopsy samples obtained from patients with
synovitis of recent onset. We also examined the synovial
expression of the gelatinases by immunohistology, as well
as their serum levels in order to determine whether these
indices may predict erosions in RA patients.
Patients and method
Patient population
A total of 66 patients that formed a subset of a larger early
synovitis cohort, recruited into an ongoing US National Insti-
tutes of Health  protocol (94-AR-0194), were selected for
analysis on the basis of having stored optimum cooling tem-
perature (OCT) compound samples available for analysis.
The patients had peripheral joint synovitis with duration
longer than 6 weeks but less than 12 months. After the
initial evaluation they were followed prospectively for 12
months. Of those patients, 45 fulfilled the American College
of Rheumatology criteria for RA [21], seven patients fulfilled
the European Spondylarthropathy Study Group criteria for
spondylarthropathies [22], and 14 could not be classified
and were diagnosed with undifferentiated arthritis.
Serum aliquots obtained at the initial visit were used for
the analysis of serum MMP and tissue inhibitor of metallo-
proteinase (TIMP) levels. All patients underwent a closed
needle biopsy of synovial tissue [23] from an inflamed
joint, typically a knee. Tender and swollen joint counts
were obtained from 66 joint areas; hips were excluded.
Anterioposterior and lateral radiographs of the hands and
feet were obtained at the initial visit and at 1-year follow-
up visit. Radiographs were read by experienced radiolo-
gists, who were unaware of the patient’s diagnosis or test
results, and were scored for erosions. Erosions were
defined as unequivocal loss of cortical and subcortical
bone in at least two different joints of either the hands or
feet. Of the 66 patients who underwent a clinical evalua-
tion and analysis of serum MMP levels, 28 had synovial
tissue biopsies with detectable lining layer and large
enough samples to determine MMP and TIMP expression
by gel zymography and immunohistochemistry.
Healthy volunteers (n=4) were recruited under the same
protocol and a synovial knee biopsy was performed once
signed informed consent was obtained. These tissues
were also assayed by gel zymography and stained
immunohistochemically.
Antibodies and gels
Antibodies to MMP-2 (immunoglobulin G1), MMP-9
(immunoglobulin G1) and MMP-14 (immunoglobulin G1)
were purchased from Research Diagnostics Inc (Flanders,
NJ, USA). The TIMP-2 (immunoglobulin G1) antibody was
obtained from Calbiochem (La Jolla, CA, USA). Polyclonal
mouse immunoglobulin G1 was used as negative control
in the staining experiments. Enzyme-linked immunosorbent
assay (ELISA) kits for serum MMP-1, TIMP-1 and TIMP-2,
and the activity assays for MMP-2 and MMP-9 were pur-
chased from Biotrak (Amersham Pharmacia Biotech, Pis-
cataway, NJ, USA). Precast zymography gels containing
10% Tris glycine with 0.1% gelatin as substrate were pur-
chased from Novex (San Diego, CA, USA), and protein
quantification kits were purchased from Bio-Rad Laborato-
ries (Hercules, CA, USA).
Matrix metalloproteinase and tissue inhibitor of
metalloproteinase enzyme-linked immunosorbent assay
ELISA assays for MMP-1, TIMP-1, and TIMP-2 were per-
formed according to the manufacturer’s instructions.
Briefly, 100ml diluted serum samples were pipetted in
duplicates into the appropriate ELISA microtiter wells and
incubated for 2h at 20–25°C. Wells were washed and
incubated with 100ml of the antiserum for 2h at 20–25°C,
and incubated with 100ml of the peroxidase conjugate for
1h. After washing 100ml of 3,3¢,5,5¢-tetramethylbenzi-
dine/hydrogen peroxide substrate were pipetted into the
wells and incubated for 30min at room temperature.
Absorbance at 630nm was measured spectrophotometri-
cally in an automated plate reader.
Serum matrix metalloproteinase activity assays
Active and total MMP-2 and MMP-9 were measured by
activity assays. Assays were performed according to the
manufacturer’s instructions. Briefly, 100ml diluted serum
samples were plated in quadruplicate and refrigerated at
4°C overnight. Plates were washed in an automated plate
washer and 50ml of a 1mol/l p-aminophenylmercuric
acetate, which activates pro-MMP, was added only into
duplicate wells in which total MMP activity was to bemeasured. After 2h of incubation at 37°C, 50ml detection
reagent containing a modified urokinase and S-2444
peptide substrate was added to all wells. Plates were
read spectrophotometrically at time 0 and after a 2-h
incubation at 37ºC for 2h at an absorbance of 410nm.
MMP activity was represented by the change of
absorbance over time. These values were compared with
a standard curve of serial dilutions of a known concentra-
tion of activated enzyme. Normal range of values was pro-
vided by the manufacturer.
Gel zymography
Gel zymography on synovial tissue samples was per-
formed according to a protocol developed by Kleiner et al
[20]. Unfixed cryosections of synovial tissue, obtained
from closed needle biopsies as described above, were
scraped off the slide with a 22-gauge needle, transferred
into a microfuge tube, and vortexed. Media from a HT-
1080 fibrosarcoma cell line was used as a positive control
for MMP-2 and MMP-9 activity. Of each sample suspen-
sion, 30ml were loaded onto a precast sodium dodecylsul-
fate- polyacrylamide gel electrophoresis (SDS-PAGE)
containing 0.1% gelatin. After electrophoresis, gels were
washed in 2.5% Triton X for 3h and incubated at 37°C in
low salt collagenase buffer containing 50mmol/l Tris,
0.2mol/l NaCl, 5mmol/l anhydrous CaCl2, and 0.02% Brij
detergent. The gels were subsequently stained with 0.5%
Comassie blue (G-250), destained with 30% methanol
and 10% acetic acid, and incubated in 30% methanol and
5% glycerol. They were dried between cellophane sheets.
Areas of gelatinase activity appeared as nonstaining
bands on the gels.
The zymography gels were scanned and analyzed using
US National Institutes of Health Image 1.6 software. Inte-
grated pixel density for each gelatinolytic band was
recorded and reported in volume units of pixel intensity
×mm2. Each value was normalized against the protein
concentration, determined by a protein quantitation kit
according to the manufacturer’s instructions, and reported
as gelatinase activity in nanograms per milligrams of
protein. Gelatinolytic bands at 92, 72, and 62kDA repre-
sent latent MMP-2, latent MMP-9, and active MMP-2 activ-
ity, respectively.
Immunohistochemistry
Immunohistochemistry was performed according to stan-
dard techniques [24]. OCT-embedded synovial tissue was
cryosectioned into 8-mm thick sections and acetone fixed
on glass slides. After hydration and blocking of endoge-
nous peroxidase activity, tissues were blocked with a dilu-
tion of human and goat serum. Sections were incubated
with primary antibody at the following concentrations:
MMP-2 (1:75), MMP-9 (1:75), TIMP-2 (1:75), and
MMP-14 (1:30). Negative controls using either mouse
immunoglobulin G1 antibodies or no primary antibody
were performed with each experiment. Slides were
washed and incubated with goat antimouse biotinylated
antibody at a 1:750 dilution followed by incubation with
streptavidine horseradish peroxidase. Slides were devel-
oped with a substrate chromogen solution until a brown
reaction product was observed, then counterstained with
hematoxylin and coverslipped.
Histologic evaluation of the synovial tissue
Synovial tissues suitable for analysis were histologically
evaluated for the presence and degree of inflammation. All
tissues were analyzed in a blinded manner by two inde-
pendent observers. Proliferation of the lining layer, inflam-
matory cellular infiltration of the sublining layer,
lymphocytic aggregates, and stromal proliferation were
scored semiquantitatively from 0 to 3 in five high-power
fields (HPFs; 400×) for each category. Scores were
added and divided by four to derive a tissue composite
index. Tissue scores for MMP expression were obtained
by counting the number of positive cells in the lining layer
and sublining layer (one HPF underneath the lining layer)
in five representative HPFs (400×) and expressed as posi-
tive cells/HPF.
Statistical methods
Differences between patient groups were analyzed using
c2, analysis of variance, and Kruskal–Wallis tests.
Results
Patient clinical features
The clinical features of the 66 patients studied are shown
in Table 1. Patients with RA were older, had more tender
and swollen joints, were rheumatoid factor positive, and
were more likely to be on disease-modifying antirheumatic
drug therapy than were non-RA patients. Of the patients
with RA, 12 had erosions at multiple sites by 1 year,
whereas none of the non-RA patients had developed defi-
nite erosions. Patient characteristics in the subset of 28
patients who underwent synovial tissue immunohistology
and gel zymography did not differ significantly from the
larger sample (data not shown).
Serum levels of the metalloproteinases and their inhibitors
in patients with early synovitis
MMP-1 serum concentrations in all 66 (100%) patients
examined were elevated, as were total MMP-9 levels in 14
(21%), TIMP-1 levels in 65 (98%), and TIMP-2 levels in 14
(21%) patients (Table 2). Serum levels were not elevated
over the normal range provided by the manufacturer.
Patients with erosive disease had higher serum MMP-1
and mean C-reactive protein (CRP) levels than patients
without erosion (P<0.01). Levels of MMP-1, but not of
other MMPs, significantly correlated with the CRP levels
(r=0.42;  P<0.001). Overall serum MMP-2 and MMP-9
levels did not correlate with tissue expression of these
enzymes (data not shown).
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expression in synovial tissue
Expressions of MMP-2, MMP-9, MMP-14, and TIMP-2 in
representative locations in the synovial tissue specimens
are shown in Figure 2. Of note, the antibodies used to
detect MMP-2 recognized only the latent zymogen form.
MMP-2 was widely expressed in the synovial lining layer
and in areas of stromal proliferation in the sublining and
stromal layer. MMP-9 expression was more focal and was
observed sparsely in the lining layer and in the endothe-
lium of single vessels in both RA and non-RA tissues.
MMP-14 and TIMP-2 were detected primarily in the lining
layer on consecutive tissue sections.
Comparisons of tissue levels of MMP-2, MMP-9, MMP-14,
and TIMP-2
MMP expression was assayed in 21 RA tissues and seven
non-RA tissues, and results were compared among
groups and with tissues from four healthy volunteers
without evidence of an arthropathy or traumatic injury
(Table 3). Tissue composite indices of inflammation were
similar in the RA and non-RA tissues. Five of the 21 RA
patients had erosions at multiple sites, as compared with
none of the non-RA patients. Synovial tissue expressions
of MMP-2, MMP-14, and TIMP-2 were virtually unde-
tectable in all normal volunteers; MMP-9 expression was
observed in an isolated area of one normal synovial tissue
sample. Tissue expression for MMP-14, the activator for
pro-MMP-2, was significantly higher in RA than in non-RA
patients (8.4±5 versus 3.7±4 cells/HPF; P=0.009). In
contrast, the expression of TIMP-2, an inhibitor of MMP-2,
was lower in the RA than in the non-RA samples (25±12
versus 39±9 cells/HPF; P=0.01). Activated and latent
MMP-2 activities, as measured by gel zymography, tended
to be higher overall in the RA patients than in the non-RA
patients, but results were not statistically different.
Radiographic erosions are associated with higher MMP-2
activity in the synovial tissue
The results of synovial tissue MMP-2 and MMP-9 expres-
sions were compared among patients with erosive
disease, patients without erosions, and normal volunteers
http://arthritis-research.com/content/2/2/145
Table 2
Determination of serum matrix metalloproteinase and tissue inhibitor of metalloproteinase concentrations
Normal range† RA (n = 45) Non-RA (n = 21) Erosions (n = 12) No erosions (n = 54)
MMP-1 (ng/ml) 0 4.0 ± 5.5 1.9 ± 2.7 7.1 ± 6.7* 2.5 ± 4.0
MMP-2 (total; ng/ml) 156–254 115 ± 50 112 ± 28 103 ± 25 116 ± 47
MMP-2 (active) N/A 15 ± 15 15 ± 14 10 ± 8 16 ± 13
MMP-9 (total; ng/ml) 13–61 44 ± 32 49 ± 34 40 ± 35 46 ± 32
MMP-9 (active) N/A 2.3 ± 3.3 3.3 ± 3.6 2.8 ± 3.5 1.6 ± 3.3
TIMP-1 (mg/ml) 0.3–0.5 1.6 ± 0.7 2.0 ± 0.9 1.5 ± 0.6 1.7 ± 0.8
TIMP-2 (ng/ml) 29–108 105 ± 166 72 ± 134 140 ± 168 85 ± 54
CRP (mg/dl)  <0.4 2.0 ± 3.9 2.2 ± 2.4 3.2 ± 3.2* 1.9 ± 2.8
Values are expressed as mean ± standard deviation of serum matrix metalloproteinase (MMP) levels measured in 66 patients. Comparison groups
were divided into rheumatoid arthritis (RA) and non-RA patients, and subsequently into patients with erosive and nonerosive disease. Erosions
were defined as definite erosions in more than one joint (see Patients and method). †Normal values provided by the manufacturer of the ELISA kit.
Normal values were not available for the assays for active MMP-2 and MMP-9. *P <0.01. CRP, C-reactive protein; TIMP, tissue inhibitor of
metalloproteinase.
Table 1
Patient description of demographic, clinical and treatment
characteristics
RA Non-RA
(n = 45) (n = 21) P
Age (years) 47 ± 13 40 ± 13 0.02
Female (%) 28 (62) 8 (38) NS
Caucasian (%) 38 (84) 21 (100) NS
Total joint count (n) 23 ± 12 7 ± 9 <0.0001
Swollen joint count (n) 17 ± 12 5 ± 8 <0.0001
ESR (mm/h) 45 ± 31 41 ± 34 NS
CRP (mg/dl) 2.2 ± 2.4 1.9 ± 3.9 NS
RF >20 (n) 32 (71) 0 <0.0001
Erosions (%) 12 (27) 0  0.006
Prednisone (%) 14 (31) 3 (14) NS
DMARD (%) 10 (22) 1 (5) 0.07
Antibiotics (%) 5 (11) 2 (10) 0.8
Comparisons were made between groups. Values are presented either
as means ± standard deviation or as total numbers (%).CRP,
C-reactive protein; DMARD, disease-modifying antirheumatic drug;
ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis;
RF = Rheumatoid factor.(Fig.1). Patients with erosive disease had significantly
higher synovial levels of total MMP-2 (10.9±8.1 versus
18.9±9.4ng/mg; P=0.04) and active MMP-2 (3.5±2.1
versus 1.9±2.5ng/mg; P=0.04) than patients without
erosions. Similarly, mean MMP-9 activity was higher in
tissue samples from patients with erosive disease, but
wide variations in tissue expression resulted in poor dis-
crimination between groups. As expected, synovium of
normal volunteers had significantly lower MMP-2 activity
than that of the patients (5.7±0.7 versus 12.3±8.7ng/mg;
P<0.05). This trend was also observed for MMP-9, but
did not reach statistical significance, probably due to
the very wide standard deviation (4.0±1.3 versus
28.6±71.2ng/mg in normal individuals and in the
patients, respectively; P=0.07).
Discussion
Joint destruction is one of the hallmarks of erosive
arthropathies and leads to significant morbidity and dis-
ability. Newer imaging studies have concluded that
erosion formation can occur very early in the disease [25].
Detailed pathologic studies, although generally performed
on destroyed joints obtained at the time of arthroplasty,
have suggested that these erosions result from direct inva-
sion of synovial tissue into the adjacent articular bone and
cartilage. It has been postulated that the locally invasive
Table 3
Immunohistologic and zymographic expression of matrix metalloproteinases in synovial tissues from patients with recent onset of
arthritis
RA (n = 21) Non-RA (n = 7) Normal tissue (n = 4)
Immunohistology
Composite inflammatory index (0–4) 1.5±0.5 1.7±0.9 0±0.1††
MMP-2  50 ± 30  78 ± 45  0††
MMP-14  8.4 ± 5**  3.7 ± 4 0††
TIMP-2  25 ± 12 39 ± 9* 0††
MMP-9 10.9 ± 6 7.4 ± 7 1 ± 0††
Gelatinolytic activity
Active MMP-2 activity (ng/mg) 2.6 ± 2.7 1.3 ± 1.1 1.3 ± 0.5
Total MMP-2 activity (ng/mg) 13.6 ± 9.6 8.6 ± 3.5 5.7 ± 0.7†
MMP-9 activity (ng/mg)  18.0 ± 28.9 60.3 ± 136 4.0 ± 0.7
For definition of ‘composite index’, refer to the Patients and method section. *P <0.05, **P <0.01, versus nonrheumatoid arthritis (RA) patients;
†P<0.05, ††P<0.01, versus normal volunteers. MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.
Figure 2
Matrix metalloproteinase (MMP)-2, MMP-9,
MMP-14 and tissue inhibitor of
metalloproteinase (TIMP)-2 expression in
synovial tissue. (a) MMP-2 expression;
(b) MMP-9 staining; (c) MMP-14 expression;
(d) TIMP-2 expression; (e) no primary
antibody; (f) mouse immunoglobulin G1
(isotype control).
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transformed phenotype, and analogies to invasive cancer
cells have been made [26]. Several metalloproteinases
that are capable of the proteolytic degradation of extracel-
lular matrix are thought to play a major role in the dissolu-
tion of the bone and cartilage matrix, allowing the invasive
cells to migrate into the stroma across cell boundaries.
Although the relative contribution of each MMP to this
process remains unclear, the gelatinases, particularly
MMP-2, appear to play a prominent role in tissue invasion
[16]. In patients with arthritis, most studies have concen-
trated on the contribution of MMP-9 to the underlying
mechanism of joint destruction. In contrast to MMP-2,
MMP-9 levels tend to be higher in inflammatory
arthropathies than in traumatic, osteoarthritic, and tissue
repair processes [11,12,27]. Furthermore, these two
MMPs differ in tissue distribution and transcriptional regu-
lation. These observations suggest that MMP-2 and
MMP-9 may contribute differentially to the pathophysio-
logic processes that lead to joint destruction.
In the joint, MMP-9 is expressed in macrophages in the
synovial lining layer, in vascular endothelial cells, leuko-
cytes, chondrocytes, and osteoclasts. It is also expressed
on cultured fibroblasts and on activated fibroblasts in vivo
[11,28]. MMP-9 is inducible by inflammatory cytokines
such as tumor necrosis factor-a and interleukin-1 [19,29],
and the post-transcriptional regulation in vivo remains
incompletely understood. MMP-9 is secreted in an inactive
zymogen form and can be activated in vitro by the plasmin
cascade and through other MMPs [30–33]. In its inactive
form MMP-9 is complexed to TIMP-1 [34]. The regulation
of MMPs by inflammatory cytokines, and the expression of
MMP-9 in macrophages and vascular structures have pre-
viously suggested that MMP-9 may be associated with the
synovial inflammation and neovascularization [35,36].
In contrast to MMP-9, MMP-2, in the inactive zymogen
form, is constitutively expressed by many cell types,
including fibroblasts and endothelial cells, and is involved
in many aspects of normal tissue remodeling and angio-
genesis [37,38]. Its unique regulatory requirements at the
cell surface have suggested a special role for MMP-2 in
tissue invasion. The transcriptional and post-translational
activation of this enzyme is tightly regulated [16]. MMP-2
differs from several other members of the metallopro-
teinase family in that its transcription is not induced in
response to the proinflammatory cytokines tumor necrosis
factor-a and interleukin-1, and seems primarily regulated
post-translationally. As is characteristic of most of the
MMPs, MMP-2 is produced as a proenzyme, and requires
activation by enzymatic cleavage. Evidence from several
investigators has suggested that MMP-2 in its active form
is bound in a trimolecular complex at the cell surface
[39–42]. Pro-MMP-2 complexed with TIMP-2 binds to a
TIMP-2 binding site on the membrane-bound MMP-14
receptor, and through a conformational change the cat-
alytic domain becomes exposed forming the active
enzyme complex. Upon dissociation from the MMP-14
receptor, TIMP-2 binds the catalytic site and suppresses
the activity. Thus, the activity of MMP-2 is regulated locally
by a delicate balance between MMP-14 activation and
TIMP-2 inhibition. Studies have localized this trimolecular
complex to the invadopodia of malignant cells at sites of
tissue invasion into stroma [43,44] and serum levels and
high tissue expression levels of active MMP-2 are predic-
tors of disease severity and shortened survival in several
malignancies [15,16].
In view of the analogies between erosion formation in
arthritis and tumor invasion in cancer, we hypothesized
that activated MMP-2 and possibly MMP-9 might play an
important role in the early stages of invasion of synovial
pannus into bone and cartilage. Synovial tissue specimens
obtained from a cohort of patients with early synovitis
were examined for the presence of MMP-9 and compo-
nents of the MMP-2-associated trimolecular complex. A
highly sensitive zymographic technique was used to evalu-
ate tissue levels of active and latent MMP-2. Our immuno-
histologic data suggest that MMP-2, TIMP-2, and MMP-14
are all localized to the synovial lining layer. Previous
reports have found colocalization of these molecules in
areas of tissue remodeling, loosening of prosthetic joints
[45–47], and in the cartilage–pannus junction [14].
Although the results of these experiments do not prove
that the expression of these molecules occurs on the
same cell, they are consistent with the view that the syn-
ovial lining layer is a site of MMP-2 activation.
Because of the blind nature of the biopsy technique used
in the present study, we did not specifically sample areas
of synovium directly adjacent to cartilage and bone. We
did, however, ensure that all of the needle biopsy samples
examined immunhistologically and zymographically had
clear evidence of a well-defined synovial lining layer, were
of adequate size, and were thus appropriate for compara-
tive evaluation. The selection of biopsy material with
detectable lining layer and sufficiently large size for analy-
sis may have biased our results toward patients with more
proliferative synovial lesions, and possibly more severe
disease. This selection bias would have occurred in the
RA and non-RA patients, however, and is therefore
unlikely to account for the differences seen in MMP-2
activity between the patient groups. We compared the
synovium of patients with early RA with that of patients
with other forms of early synovitis, and with that of normal
volunteers. The RA samples tended to have the highest
expression levels of MMP-2 and MMP-14, but they exhib-
ited low levels of TIMP-2 expression. More importantly, we
showed that the patients with radiographic erosions, all of
whom had RA, had the highest levels of active MMP-2
by gel zymography. We therefore propose that the
http://arthritis-research.com/content/2/2/145augmented levels of activated MMP-2 detected in the
synovia of patients with early erosive RA may relate, at
least in part, to an imbalance between activation by
MMP-14 and inhibition by TIMP-2.
Immunohistologically, MMP-9 expression was clearly
higher in inflamed synovium than in normal synovium,
where it was virtually undetectable. Furthermore, MMP-9
activity levels tended to be higher in the synovial samples
of patients with radiographic erosions than those of
patients without erosions, but the measured values varied
widely in the specimens examined. The focal expression of
MMP-9 in these synovial tissues, combined with the small
number of samples examined, might have contributed to
the wide tissue variations observed.
Overall, the present observations suggest an association
between the presence of active synovial gelatinases and
the early development of erosive articular damage.
Although the evidence is indirect, these data are consis-
tent with the hypothesis that high levels of activated syn-
ovial gelatinases reflect augmented synovial invasiveness;
these observations are similar to those made in the
context of invasive cancers [16]. Although there continues
to be controversy regarding the origins of the invasive
cells at the junction of cartilage/bone and pannus, consid-
erable evidence has accumulated that the lining cells in
RA synovium exhibit a ‘transformed’ phenotype that is
typical of invasive cells [26,48].
We attempted to evaluate the more readily available
serum levels of active MMPs as predictors of joint ero-
sions. Overall, only the serum levels of MMP-1 were signif-
icantly associated with erosions and with CRP levels.
Persistent CRP elevation in RA patients has been shown
to be associated with the progression of radiographic ero-
sions [49], but a previous RA study failed to associate
MMP-1 levels with erosions [50]. In general, serum levels
of MMPs have tended to vary widely in the reported
studies [9,11,12,51], and appear not to be of prognostic
value. Furthermore, degranulation of platelets and neu-
trophils may contribute to the elevation of serum levels of
MMP-2 and MMP-9 seen in the patients, and may be an
explanation for the high baseline level in the serum
[52,53]. In contrast, this is not the case for MMP-1,
because no blood cell carries a preformed secretory
granule of this enzyme and this may explain why MMP-1
levels relate more closely to radiographic erosions. The
measurement of serum MMP levels in the context of con-
trolled therapy trials has not been well explored.
In the present study we provided evidence that active
MMP-2 complexes are expressed in the synovium and may
be involved in the development of bony erosions. Thera-
peutic strategies to inhibit a broad spectrum of MMPs,
including MMP-2 and possibly MMP-9, may therefore
present a more powerful approach to retard or prevent
early erosions in patients with an inflammatory arthropathy.
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